Ipsen Presents Its 2019 Results, Provides 2020 Guidance and Updates 2022 Financial Outlook
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: Business Wire
PARIS--(BUSINESS WIRE)--Regulatory News:Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2019.Group sales growth of 15.8% as reported or 14.8% at constant currency and scope of consolidation1, driven by Specialty Care sales growth of 17.2%1, reflecting strong performance across all major products and geographies, while Consumer Healthcare sales were down -1.2%1Core Operating margin at 30.4% of net sales, up 0.7 points. IFRS Operating margin at -1.3% of net sales, down 24.6 pointsSetback in the palovarotene program of partial clinical hold for all patients under 14 years of age and reaching pre-specified second interim analysis futility criteria in the Phase 3 MOVE trial for fibrodysplasia ossificans progressiva (FOP), leading to a partial impairment of €669 million before taxCore consolidated net profit of €563 million (+14.6% vs. 2018), with fully diluted Core EPS growing by 14.1% to reac
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Ipsen appoints Keira Driansky as EVP, President of North AmericaGlobeNewswire
- Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidanceGlobeNewswire
- Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningenPR Newswire
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesPR Newswire
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesPR Newswire